Sector News

Lupin sells off Japanese operation to tidy up its balance sheet

November 11, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Even as other drugmakers are making big plays for business in Japan, India’s Lupin is backing off. Just weeks after selling the sterile manufacturing assets of its Kyowa operation, it has now unloaded the rest of Kyowato a private equity investor.

Lupin today announced it will sell Kyowa Pharmaceutical Industry Co. to Japanese private equity fund Unison for ¥57.4 billion ($526 million) and expects to net about ¥32.6 billion ($300 million) on the deal. Lupin acquired the business in 2007 for about $60 million

The deal includes manufacturing facilities in Sanda and Tottori, Japan and a R&D center at Osaka, Lupin said.

“This transaction is aligned with our vision to focus on our key markets and strategic priorities to achieve sustainable growth in the mid to long-term,” Lupin CEO Vinita Gupta said in a statement. “The deal proceeds will be utilized to strengthen Lupin’s balance sheet as well as provide growth capital to support organic and inorganic initiatives for our focus markets.”

The operation makes a variety of generic products but Lupin said it is particularly strong in the “central nervous system/neurology space.” With about $260 million in sales in fiscal 2019, Lupin said the Kyowa operations ranks fifth in the Japanese generic market.

This deal comes three months after Lupin sold the sterile injectables plant and portfolio of Kyowa to Abu Dhabi-based Neopharma for an undisclosed sum. It also comes as Lupin has been dealing with FDA concerns over some of its manufacturing that will likely require investments. The FDA in September issued a warning letter for Lupin’s finished dose plant in Mandideep, India.

The Lupin Kyowa deal is actually part of a Japan M&A double feature. Novartis’ Sandoz unit announced it is buying the Japanese operations of South Africa’s Aspen Pharmacare for up to €400 million. In that case, Aspen will continue to manufacture drugs for Sandoz for up to seven years. That deal comes as Novartis has yet to complete a $1 billion sale of some plants and a portfolio of 300 drugs to India’s Aurobindo as it tries to remake its exposure in the difficult U.S. generics market.

By Eric Palmer

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

December 4, 2019

Horizon looks to the future with massive San Francisco manufacturing, R&D plant

Life sciences

LinkedIn Twitter FacebookHorizon Therapeutics, once known for its primary care drugs, is looking to pivot further to rare diseases with the FDA scrutinizing its late-stage inflammatory eye disease candidate. In […]

December 2, 2019

Could AI create a brave new world of pharma R&D?

Life sciences

LinkedIn Twitter FacebookArtificial Intelligence (AI) has become the latest buzz word in drug R&D, and many of the world’s biggest pharma companies claim to be using it to drive forward […]

December 2, 2019

Big pharma agrees to drastically cut prices of blockbuster drugs in China

Life sciences

LinkedIn Twitter FacebookChina’s National Healthcare Security Administration (NHSA) has announced it has agreed an average 61% cut in prices of 70 top-selling drugs with large pharma manufacturers in exchange for […]

Subscribe to our Weekly Newsletter

We're easy to reach